Simon Cherry has made significant contributions to biomedical imaging instrumentation and technology development, including microPET and hybrid PET/MRI systems. He is widely recognized for his work on molecular imaging and has received numerous awards for his achievements.
Researchers have demonstrated that combining targeted radionuclide therapy with immunotherapy can enhance treatment response and lead to a high cure rate in melanoma patients. This novel approach uses yttrium-86 (Y-86) NM600, which selectively targets tumors and delivers precise radiation doses.
A novel PET tracer has been developed to accurately image cardiovascular infections, which are extremely dangerous and have a high fatality rate. The tracer, called 6'-[18F]Fluoromaltotriose, is transported into bacterial cells by a membrane transport system exclusive to bacteria, allowing for specific imaging of bacterial infections.
Researchers developed a novel PSMA-targeting agent by conjugating MCG with an albumin-binding Evans blue derivative, improving tumor delivery and increasing the therapeutic effect. The agent showed significant tumor growth inhibition and complete eradication of tumors in mice, suggesting a promising strategy for cancer management.
Researchers have developed a new nuclear medicine procedure that can safely and effectively detect cancerous gastrointestinal and pancreatic neuroendocrine tumors. The novel radiolabeled tracer Ga-OPS202 has been shown to improve imaging contrast and sensitivity for detecting primary tumors or liver metastases.
A novel PET imaging method uses antibody fragment probes to target immune cells, detecting inflammation in the bowel and potentially guiding biopsies. The technique has wide applications in various diseases and could unlock assessment of inflammation.
Researchers developed a novel PET tracer that targets joint inflammation and can visualize active inflammation sites in arthritic joints. The tracer, fluorine-18 F-FEDAC, shows promise for early detection of rheumatoid arthritis, potentially improving treatment outcomes.
Researchers developed a DOTA-conjugated NTR1 antagonist to treat and monitor pancreatic cancer, showing significant tumor growth inhibition in early studies. The novel procedure was well-tolerated by patients, with one experiencing improved symptoms and quality of life.
A new PET tracer has shown potential in predicting treatment effectiveness for depression by measuring the level of serotonin transporter protein in the brain. The study found that patients who responded to treatment had lower levels of this protein before treatment began, suggesting a biomarker for remission.
Researchers have developed a new PET imaging agent that targets NMDA receptors in nerve cells to assess treatments for various neurological diseases. The agent, C-Me-NB1, provides valuable insights into the role of NMDA receptors in brain disorders.
A novel nuclear medicine imaging agent targeting copper accumulation in tumors detects prostate cancer recurrence early in patients with biochemical relapse. The new imaging agent, copper-64 chloride (64CuCl2), has a higher detection rate than fluorine-18-choline-PET/CT in patients with low levels of PSA (<1 ng/ml).
Researchers developed a new approach that uses a single PET scan to assess PD-L1 positive tumors, enabling personalized cancer treatment. The study demonstrates the feasibility of this non-invasive method, which may help guide treatment decisions and assess treatment response.
The Society of Nuclear Medicine and Molecular Imaging and the American Society of Nuclear Cardiology have issued joint guidelines for the clinical quantification of myocardial blood flow using Positron Emission Tomography (PET). The guidelines provide a comprehensive framework for the measurement and interpretation of myocardial blood ...
Researchers have developed a new method to differentiate cancerous tissue from healthy tissue in prostate cancer patients using PSMA PET/CT scans. The study found that a cutoff value of SUV max = 3.15 can accurately diagnose prostate cancer with high sensitivity and specificity.
PSMA PET/CT detects prostate cancer recurrence earlier than current imaging modalities, enabling more effective salvage radiotherapy. Nearly half of patients with biochemical recurrence show positive results, with lesions often found in bone and perirectal lymph nodes.
A new radiotracer, 18F-FDS, has been developed to identify and track bacterial infections in the lungs. The tracer was tested on mice with live bacteria or dead bacteria to induce inflammation, and it successfully differentiated between lung infection and inflammation.
The Society of Nuclear Medicine and Molecular Imaging has published appropriate use criteria (AUC) for somatostatin receptor PET imaging in neuroendocrine tumors. This AUC addresses several clinical scenarios for diagnosing neuroendocrine tumors (NETs).
The new total-body PET/CT scanner will advance clinical research and patient care by providing better imaging data from the whole body, reducing radiation exposure and increasing sensitivity. This technology has the potential to change cancer detection and staging methods, as well as improve diagnosis for other systemic conditions.
A new PET tracer has been developed to effectively gauge the effectiveness of promising Alzheimer's treatments in mouse models. The tracer binds to BACE1, a key enzyme involved in amyloid-β development, and accurately measures its effects on brain metabolism, neuroinflammation, and amyloid-β pathology.
A study by Australian researchers demonstrates that PSMA PET scans can identify prostate cancer patients who would benefit from salvage radiation treatment. The study shows an overall treatment response of 72 percent, with men having negative or fossa-confined PSMA having the highest treatment response to SRT.
A new nuclear medicine test can identify kidney transplant infection in non-invasive procedures, using positron emission tomography/magnetic resonance imaging (PET/MRI). The test has the potential to refine characterization of infectious and inflammatory kidney diseases.
Researchers found that cell-free tumor DNA circulating in the bloodstream correlates with tumor metabolism rather than tumor burden in advanced non-small cell lung cancer patients. This study suggests that circulating tumor DNA may be a reliable biomarker to identify potential unresponsive NSCLC patients before treatment.
Researchers developed a new three-step system targeting and eliminating colorectal cancer using nuclear medicine. The treatment achieved a 100-percent cure rate in mouse models without toxic effects.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/CT imaging in cancer patients. The AUC aims to improve the utilization of this technology and provide guidance for providers across specialties.
A novel PET tracer, 6"-18F-fluoromaltotriose, has been developed to identify most bacterial infections. The agent is a derivative of maltose and targets the maltodextrin transporter in bacteria, allowing for non-invasive detection and monitoring of antibiotic therapy.
Collaborative nuclear medicine and radiology training options are proposed to address evolving practice needs, while an alternative view emphasizes the importance of independent training programs. Innovative theranostics advances in nuclear medicine are highlighted as a result of dedicated training programs.
Researchers report on a new dosing regimen for actinium-225 labeled targeted alpha therapy, showing promising anti-tumor response in patients with PSMA-positive tumors. The treatment protocol balances treatment response with toxicity concerns to provide effective therapy with minimal side effects.
Theranostics combines predictive biomarkers and precise therapy to target cancer cells, minimizing side effects. The field is expected to change nuclear medicine from 'nuclear radiology' to true 'nuclear medicine,' with potential for cures.
Researchers have developed a new approach to precisely identify and localize prostate cancer tumors while protecting healthy tissue. The double targeting ligand RPS-027 binds to both PSMA and albumin, reducing kidney uptake and increasing tumor-to-tissue ratios for improved therapeutic profile.
Early FDG-PET/CT scanning can accurately predict melanoma patients' response to immune checkpoint inhibitor therapy, providing a more effective treatment approach. The study developed criteria with high sensitivity, specificity, and accuracy, identifying a small increase in tumor uptake as an indication of responsiveness.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has announced the recipients of the 2017-2019 Wagner-Torizuka Fellowship. The two-year fellowship provides extensive training and experience in nuclear medicine and molecular imaging for Japanese physicians in the early stages of their careers. This year's fellows are Sho Mo...
A novel PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), demonstrates potential for imaging prostate cancer. The tracer shows elevated tumor-to-background ratios and high-contrast images in human cases, suggesting its viability as a replacement for existing tracers.
The Society of Nuclear Medicine and Molecular Imaging has published appropriate use criteria (AUC) for hepatobiliary scintigraphy in abdominal pain. The new guidelines aim to ensure cost-effective and appropriate utilization of advanced diagnostic imaging services, helping referring physicians make informed decisions.
The Society of Nuclear Medicine and Molecular Imaging recognized Robert E. Henkin, MD, for his 30-year dedication to the field of nuclear medicine, while John M. Hoffman, MD, was honored for his expertise in molecular imaging research and leadership roles in the SNMMI Clinical Trials Network.
Researchers developed a novel imaging tracer that allows for early assessment of abdominal aortic aneurysm (AAA) risk. The study shows high sensitivity and specificity in detecting vessel wall biology, suggesting a promising tool for AAA risk stratification.
The Society of Nuclear Medicine and Molecular Imaging's Technologist Section recognized the work of several award-winning nuclear medicine technologists, including Amanda Abbott, Dusty M. York, Cindi Luckett-Gilbert, Margaret M. Doonan, and Robert A. Pagnanelli, for their contributions to education and service in the field.
A Phase II study found that increasing radiotherapy doses to hypoxic non-small cell lung cancer (NSCLC) lesions, identified by PET/CT scans, did not improve patient outcomes. The study suggests that smaller volumes of tumors with hypoxia may be more effectively targeted for radiotherapy.
Researchers have developed a novel PET tracer that can detect small blood clots in veins and arteries, providing valuable information for diagnosis and treatment. The tracer binds to GPIIb/IIIa receptors, targeting the critical molecular components involved in platelet clumping.
The Journal of Nuclear Medicine ranked 5th in impact factor among medical imaging journals, increasing to 6.646 in 2016, with a 5-year impact factor of 6.459. Citations increased to 24,977, and article influence score is 1.84.
Researchers found that dual-agent PET/MR with time of flight detects more bone metastases in breast and prostate cancer patients, improving detection accuracy and reducing radiation dose. The study used combined imaging agents <sup>18</sup> F-FDG and <sup>18</sup> F-NaF to enhance image quality.
Researchers demonstrate preclinically that dual-labeled PSMA-inhibitors improve preoperative staging and intra-operative guidance for metastatic prostate cancer patients. This combined approach results in more accurate detection of PSMA-positive tumor lesions, enhancing patient outcomes.
A new imaging test, Ga-68 PSMA PET/CT, has been shown to detect cancer that conventional imaging missed, changing treatment plans for 51% of patients. The test also improved management for patients with recurrent disease, with 69% receiving radiation therapy and 64% undergoing surgery.
A single dual time-point PET scan can identify two important biomarkers of Alzheimer's disease: neuronal injury and amyloid load. This non-invasive method shows promise for early diagnosis and personalized treatment.
A new study demonstrates the feasibility and safety of HuMab-5B1, an antibody that targets the cancer antigen 19-9, found on pancreatic tumors and other malignancies. The treatment shows promise for better identifying tumors and directing treatment.
The Society of Nuclear Medicine and Molecular Imaging recognized seven new SNMMI Fellows for their distinguished service and exceptional achievements in the field. The fellows include past SNMMI presidents, renowned experts, and leaders in nuclear medicine and molecular imaging.
Researchers developed a personalized peptide-receptor radionuclide therapy (PRRT) approach, which increased the radiation dose to tumors by up to three times. The treatment showed reduced side effects and improved safety profiles without compromising therapeutic benefits.
A Phase III trial shows that peptide-receptor radionuclide therapy significantly improves patient wellbeing, particularly in advanced midgut neuroendocrine tumors. Lutathera treatment provided more relief for patients than high-dose octreotide, with improved quality-of-life metrics and fewer side effects.
Researchers found that combining peptide-receptor radionuclide therapy (PRRT) with a PARP inhibitor significantly slows the growth of neuroendocrine tumors. The treatment combination induced more cell death and inhibited cell proliferation in both gastroenteropancreatic and bronchopulmonary NET cell lines.
Pomper is recognized for his work on developing new imaging agents targeting cancer and central nervous system processes. He oversees several federally funded programs at Johns Hopkins, advancing the field of molecular imaging.
Researchers demonstrated the efficacy of targeted photodynamic therapy (tPDT) to treat prostate cancer before and during surgery, using a PSMA-targeting agent coupled with photosensitizers. The technique optimizes prostate cancer care by allowing visualization of tumors prior to surgery and providing real-time guidance to surgeons.